- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00624923
Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD)
Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD)
The hypothesis is that western lifestyle, with sedentary behaviors and caloric excess promote a chronic, subacute inflammatory state that participates in the development and progression of atherosclerosis. We will evaluate the effects of targeting inflammation using the anti-inflammatory drug salsalate, compared to placebo, on coronary artery plaque volume assessed by multi-detector computed tomographic angiography (MDCTA). The TINSAL-CVD study is a randomized, double-masked, placebo-controlled, 2 arm, clinical trial.
The purpose of the study is to compare the effect of salsalate or placebo on sub-acute inflammation and coronary plaque, in people with cardiovascular disease. Participants are randomized to active intervention (salsalate) or placebo interventions for a period of 30 months. The primary endpoint is change in plaque volume in the coronary arteries assessed by MDCTA from baseline to 30 months.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVE:
To determine whether targeting inflammation using salsalate compared with placebo reduces progression of noncalcified coronary artery plaque.
DESIGN, SETTING, AND PARTICIPANTS:
In the Targeting Inflammation Using Salsalate in Cardiovascular Disease (TINSAL-CVD) trial participants were randomly assigned to 30 months of salsalate or placebo in addition to standard, guideline-based therapies. Randomization was computerized and centrally allocated, with patients, health care professionals, and researchers masked to treatment assignment. Participants were overweight and obese statin-using patients with established, stable coronary heart disease.
INTERVENTIONS:
Salsalate (3.5 g/d) or placebo orally over 30 months.
MAIN OUTCOMES AND MEASURES:
The primary outcome was progression of noncalcified coronary artery plaque assessed by multidetector computed tomographic angiography. Secondary outcomes were other measures of safety and efficacy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Maine
-
York, Maine, United States, 03939
- Seacoast Cardiology
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Joslin Diabetes Center
-
Framingham, Massachusetts, United States, 01702
- Heart Center of Metrowest
-
Milton, Massachusetts, United States, 02186
- South Shore Internal Medicine
-
Newton, Massachusetts, United States, 02462
- Newton-Wellesley Cardiology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Eligibility will be based upon the presence of established coronary artery disease including
- previous myocardial infarction (≥6 months ago), or
- previous coronary bypass surgery (> 12 months ago), or
- stable angina, or
- significant non-calcified plaque in at least one coronary artery, or
- abnormal exercise tolerance test or
- an area of reversible ischemia on nuclear imaging study or pharmacologic stress, with subsequent revascularization, or angioplasty, or
- abnormal exercise treadmill stress test with or without nuclear imaging or echocardiography with the following exclusions:
Exclusions based on nuclear imaging:
- Transient cavity dilation
- More than one vascular territory involved with reversible defect (multiple defects)
- Reversible defects involving the anterior wall, septum or apex (LAD territory)
Exclusions based on echocardiography imaging:
- More than one vascular territory involved with inducible wall motion abnormalities (multiple defects)
- Inducible wall motion abnormalities involving the anterior wall, septum or apex (LAD territory)
Subjects should be at list 6 months after a myocardial infarction and/or revascularization procedure to be eligible.
In addition, subjects must be:
- aged 21- 75 years inclusive,
- BMI ≥ 27 kg/m2 and ≤ 35 kg/m2 if female and ≤ 40 kg/m2 if male (a BMI ≥24.5 for subjects from Asian origin)
- on a stable dose of an HMG CoA reductase inhibitor (statin) for 1 month at screening or unable to tolerate a statin,
- have normal renal function, (note estimated creatinine clearance calculated using Cockcroft-Gault (CG) equation ≥60 at screening [eCrCLCG (ml/min) = [(140 - age) x weight (kg)]/[SCr(mg/dl) x 72] x [0.85 if female],
- have liver function (ALT, AST) < 3 times upper limits of normal),
- normal thyroid function (on stable dose replacement therapy is acceptable),
- if women are of child bearing potential they must have a pregnancy test prior to the CT angio and use contraception for the remainder of the study
- patients with T2D must have a fasting glucose of ≤ 200 mg/dl at screening and cannot be treated with thiazolidinedione class agents or insulin or Extendin-4 (Byetta) therapy.
Subjects must be willing to have at least three visits at the Beth Israel-Deaconess Medical Center/Joslin Diabetes Center with a baseline and a 30-month follow-up series of imaging studies including CT angiography of the coronary arteries and imaging of the aorta, abdominal adiposity and liver, and interim visit at 1 year.
Exclusion Criteria:
- Unstable angina (increase in frequency or severity of anginal episodes or development of chest pain at rest)
- significant obstructive disease (≥ 70%) in left main coronary artery, ostial LAD or three-vessel disease by MDCTA
- Significant heart failure (NYHA class III and IV)
- Current atrial fibrillation or Wolf-Parkinson-White (WPW) syndrome
- Allergy to beta-blocker in subjects with resting heart rate > 65 bpm
- Systolic blood pressure > 160 mm Hg
- Diastolic BP > 100 mm Hg
- Persons with allergies to contrast material
- History of asthma if unable to tolerate beta blocker
- Allergy to iodinated contrast material or shellfish
- Allergy to nitroglycerin
- BMI > 35 kg/m2 if female and > 40 kg/m2 if male
- Body weight > 350 lbs
- Use of drugs for weight loss [e.g. Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanolamine) or similar over-the counter medications] within three months of screening
- Surgery within 30 days of screening
- History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV)
- Poor mental function or history of dementia/ Alzheimer's Disease or on medications used for treatment of dementia [e.g. Tacrine (Cognex), Rivastigmine (Exelon), Galantamine (Razadyne, Reminyl), Donepezil (Aricept), Memantine (Namenda)] or any other reason to expect patient difficulty in complying with the requirements of the study
- Medicine for erectile dysfunction within 72 hours prior to MDCTA
- History of significant chronic rheumatologic or other chronic inflammatory disease (including foot ulcers)
- Prior hemorrhagic stroke
- persons with known aspirin allergy
- Use of continuous oral corticosteroid treatment (more than 2 weeks), or patients requiring corticosteroids within 3 months
- Anti-diabetic medication including thiazolidinedione (pioglitazone or rosiglitazone), or insulin or Extendin-4 (Byetta)
- History of peptic ulcer or gastritis within 5 years
- Positive stool guaiac
- Hemoglobin 2 standard deviations below normal
- Low platelet count (2 standard deviations below normal)
- Known bleeding disorder
- Coumadin (warfarin compounds)
- History of type 1 diabetes and/or history of ketoacidosis
- Daily use of NSAIDS (including salsalate) for arthritis
- History of malignancy, except subjects who have been disease-free for greater than 5 years, or whose only malignancy has been basal or squamous cell skin carcinoma
- History of drug or alcohol abuse, or current weekly alcohol consumption >14 units/week (1 unit = 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 ounce of alcohol)
- Use of probenecid (Benemid, Probalan), sulfinpyrazone (Anturane) or other uricosuric agents
- Chronic tinnitus.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1- Active Pharmacologic
Salsalate
|
Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
Other Names:
|
PLACEBO_COMPARATOR: 2- Placebo
Placebo
|
Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months
Time Frame: Baseline to 30 months
|
Baseline to 30 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Cholesterol
Time Frame: Baseline to 30 mo
|
secondary
|
Baseline to 30 mo
|
Change in Inflammation Marker: CRP
Time Frame: baseline to 30 mo
|
Secondary outcome of change in inflammation marker CRP
|
baseline to 30 mo
|
Change in Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), ALT
Time Frame: baseline to 30 mo
|
Secondary outcome, change in liver inflammation associated with NASH: ALT
|
baseline to 30 mo
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Francine Welty, MD, Beth Israel Deaconess Medical Center
- Principal Investigator: Ernest Schaefer, MD, Tufts Medical Center
- Principal Investigator: Melvin Clouse, MD, Beth Israel Deaconess Medical Center
Publications and helpful links
General Publications
- Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, Shoelson SE. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008 May;1(1):36-43. doi: 10.1111/j.1752-8062.2008.00026.x.
- Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006 Jul;116(7):1793-801. doi: 10.1172/JCI29069. Erratum In: J Clin Invest. 2006 Aug;116(8):2308.
- Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008 Feb;31(2):289-94. doi: 10.2337/dc07-1338. Epub 2007 Oct 24.
- Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE; TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010 Mar 16;152(6):346-57. doi: 10.7326/0003-4819-152-6-201003160-00004.
- Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013 Jul 2;159(1):1-12. doi: 10.7326/0003-4819-159-1-201307020-00003.
- Goldfine AB, Conlin PR, Halperin F, Koska J, Permana P, Schwenke D, Shoelson SE, Reaven PD. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia. 2013 Apr;56(4):714-23. doi: 10.1007/s00125-012-2819-3. Epub 2013 Jan 31.
- Avadhani R, Fowler K, Barbato C, Thomas S, Wong W, Paul C, Aksakal M, Hauser TH, Weinger K, Goldfine AB. Glycemia and cognitive function in metabolic syndrome and coronary heart disease. Am J Med. 2015 Jan;128(1):46-55. doi: 10.1016/j.amjmed.2014.08.025. Epub 2014 Sep 16.
- Goldfine AB, Shoelson SE. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest. 2017 Jan 3;127(1):83-93. doi: 10.1172/JCI88884. Epub 2017 Jan 3.
- Ridker PM. Informative Neutral Studies Matter-Why the Targeting Inflammation With Salsalate in Cardiovascular Disease (TINSAL-CVD) Trial Deserves Our Attention. JAMA Cardiol. 2016 Jul 1;1(4):423-4. doi: 10.1001/jamacardio.2016.0604. No abstract available.
- Hauser TH, Salastekar N, Schaefer EJ, Desai T, Goldfine HL, Fowler KM, Weber GM, Welty F, Clouse M, Shoelson SE, Goldfine AB; Targeting Inflammation Using Salsalate in Cardiovascular Disease (TINSAL-CVD) Study Team. Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins. JAMA Cardiol. 2016 Jul 1;1(4):413-23. doi: 10.1001/jamacardio.2016.0605.
- Day EA, Ford RJ, Smith BK, Houde VP, Stypa S, Rehal S, Lhotak S, Kemp BE, Trigatti BL, Werstuck GH, Austin RC, Fullerton MD, Steinberg GR. Salsalate reduces atherosclerosis through AMPKbeta1 in mice. Mol Metab. 2021 Nov;53:101321. doi: 10.1016/j.molmet.2021.101321. Epub 2021 Aug 21.
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Body Weight
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Cardiovascular Diseases
- Inflammation
- Overweight
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Salicylsalicylic acid
- Sodium Salicylate
Other Study ID Numbers
- CHS 06-13
- P50HL083813 (NIH)
- CCI: 2006-P-00175 (OTHER: Beth Israel Deaconess Medical Center, Boston, MA, USA)
- CHS: 06-13 (OTHER: Joslin Diabetes Center, Boston, MA, USA)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
Clinical Trials on Salsalate
-
Universidade Federal do Rio de JaneiroCompletedObesity | Obesity, AbdominalBrazil
-
Universidade Federal do Rio de JaneiroOswaldo Cruz Foundation; Rio de Janeiro State Research Supporting Foundation... and other collaboratorsCompletedDyslipidemia | Oxidative Stress
-
Gary L. PierceCompletedEndothelial Dysfunction | Vascular Stiffness | Diastolic DysfunctionUnited States
-
Joslin Diabetes CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedType 2 DiabetesUnited States
-
Joslin Diabetes CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedType 2 Diabetes MellitusUnited States
-
Indiana UniversityTerminatedVascular Function, Endothelin, and Inflammation in Pre-diabetic Obesity Versus Lean Healthy ControlsObesity | Pre-diabetesUnited States
-
University of MichiganCompletedType 1 Diabetes | Peripheral NeuropathyUnited States
-
University of MiamiCompletedSpinal Cord InjuryUnited States
-
Boston UniversityCompleted
-
Joslin Diabetes CenterNational Institutes of Health (NIH)Completed